Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BLM | P54132 | 1/20 | 0.55 |
| ▸ | WRN | Q14191 | 1/20 | 0.55 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.48 |
| ▸ | KDR | P35968 | 5/20 | 0.48 |
| ▸ | CDK8 | P49336 | 2/20 | 0.48 |
| ▸ | MEN1 | O00255 | 2/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.48 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.47 |
| ▸ | BRAF | P15056 | 6/20 | 0.46 |
| ▸ | MAPT | P10636 | 5/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | NPC1 | O15118 | 3/20 | 0.46 |
| ▸ | RAB9A | P51151 | 3/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | RAF1 | P04049 | 2/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5450981 | 0.85 | MAPT (0.59) | BLMWRNL3MBTL1MEN1KMT2A | |
| SCHEMBL5444618 | 0.84 | RAF1 (0.54) | KDRCDK8MEN1KMT2ABRAF | |
| SCHEMBL5454402 | 0.84 | BLM (0.71) | BLMWRNKDRCDK8BRAF | |
| SCHEMBL5439608 | 0.83 | MEN1 (0.48) | L3MBTL1KDRMEN1KMT2AMAPT | |
| SCHEMBL5441696 | 0.81 | BLM (0.55) | BLMWRNL3MBTL1KDRMEN1 | |
| SCHEMBL5435490 | 0.81 | LMNA (0.58) | L3MBTL1KDRCDK8MEN1KMT2A | |
| SCHEMBL5446510 | 0.81 | KMT2A (0.75) | BLMWRNL3MBTL1MEN1KMT2A | |
| SCHEMBL5439656 | 0.80 | MEN1 (0.62) | BLMWRNL3MBTL1MEN1KMT2A | |
| SCHEMBL5447957 | 0.75 | MAPT (0.56) | BLML3MBTL1KDRMEN1KMT2A | |
| SCHEMBL16621285 | 0.73 | RAF1 (0.69) | KDRCDK8MEN1KMT2ABRAF |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070191353-A1 | Use of thiadiazoleurea derivatives | MERCK PATENT GMBH (DE) | 2007-08-16 | — | — | US | claimed |
| US-20070191353-A1 | Use of thiadiazoleurea derivatives | MERCK PATENT GMBH (DE) | 2007-08-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070191353-A1 | Use of thiadiazoleurea derivatives | RAF1, ARAF, JAK1 | BLM 4089/4885WRN 3961/4885L3MBTL1 1823/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.